A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer

Abstract

BackgroundThis study compared the detection rates for clinically significant prostate cancer (CSPC) between magnetic resonance imaging and ultrasonography (MRI/US)-fusion-targeted biopsy (TB), systematic biopsy (SB) and combination of TB and SB.MethodsThis prospective study evaluated simultaneous TB and SB for consecutive patients with suspicious lesions that were detected using pre-biopsy multiparametric MRI. A commercially available real-time virtual sonography system was used to perform the MRI/US-fusion TB with the transperineal technique. The prostate imaging reporting and data system version 2 (PI-RADS v2) was assigned to categorize the suspicious lesions.ResultsA total of 177 patients were included in this study. The detection rate for CSPC was higher using SB, compared to TB (57.1% vs 48.0%, p = 0.0886). The detection rate for CSPC was higher using the combination of TB and SB, compared to only SB (63.3% vs 57.1%, p = 0.2324). Multivariate analysis revealed that PIRADS v2 category 4 and an age of <65 years were independent predictors for TB upgrading (vs. the SB result).ConclusionsPI-RADS v2 category 4 and an age of <65 years were predictive factors of upgrading the Gleason score by MRI/US-fusion TB. Thus, MRI/US-fusion TB may be appropriate for patients with those characteristics.Trial registrationThis study was retrospectively registered at the University Hospital Medical Information Network (UMINID000025911) in Jan 30, 2017.

Magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy using three‐dimensional ultrasound‐based organ‐tracking technology: Initial experience in Japan

“…These detection rates might not be simply compared with each other, as the patient backgrounds including the distribution of MRI scores and PSA are different among the biopsy reports in Japan. However, the CDRs of both any cancer and CSCa by MRUS fusion biopsy technique TB might be greater than the conventional biopsy technique in those reported previous studies . In the present study, CDRs of CSCa per patient were 45.8% in SBx versus 70.2% in MRUS TB ( P < 0.0001).…”

“…Table shows the comparison of CDRs in the recent English reports in Japanese patients . The CDRs were available for all eight trials.…”

“…In the present study, CDRs of CSCa per patient were 45.8% in SBx versus 70.2% in MRUS TB ( P < 0.0001). There were two previous reports that compared the CDRs for CSCa between MRUS TB and SBx in the Japanese population . Shoji et al .…”

Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonography‐fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system version 2 score of 3–5

“…The MRI parameters have been reported previously . T2‐weighted 3‐D/sagittal images (70 slices at 1‐mm thick per slice) were reconstructed for MRI/US rigid fusion TB.…”

“…The MRI parameters have been reported previously. 16 T2weighted 3-D/sagittal images (70 slices at 1-mm thick per slice) were reconstructed for MRI/US rigid fusion TB. A commercially available real-time virtual sonography system (Hitachi Medical Corporation, Tokyo, Japan) was used for the present study.…”